Kidney Disease News and Research

RSS

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).

17 Feb 2010

Childhood obesity: Strongest predictor of premature death

In a study now being published in The New England Journal of Medicine, Associate Professor Paul Franks of Umeå University in Sweden, in collaboration with researchers in the US, shows how childhood obesity, together with other risk factors for cardiovascular disease, affects premature death.

16 Feb 2010

Scientists discover molecular pathway to regenerate damaged kidney tissues

Scientists have discovered a molecular pathway that works through the immune system to regenerate damaged kidney tissues and may lead to new therapies for repairing injury in a number of organs.

16 Feb 2010

Simple protein urine test may help detect early kidney disease in people with lupus

Simple urine tests for four proteins might be able to detect early kidney disease in people with lupus, researchers at UT Southwestern Medical Center have found in an animal study.

16 Feb 2010

Study shows benefits of stent grafts over balloon angioplasty for patients who undergo dialysis

A randomized multicenter study of 190 patients at 13 medical centers shows-- for the first time-- the "superior" benefit of stent grafts over balloon angioplasty for maintaining function of dialysis access grafts in kidney failure patients who undergo dialysis. Until now, no other therapy has proven more effective than angioplasty.

12 Feb 2010

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

12 Feb 2010

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a Phase I clinical trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).

11 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

Researchers investigate risk factors for childhood obesity

Both genetics and parents who comfort their infants with food are the focus of a study funded for $1 million by the National Institute of Diabetes and Digestion and Kidney Disease investigating risk factors for childhood obesity.

11 Feb 2010

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

Low potassium levels increase risk of death in patients with heart failure and CKD

New research from the University of Alabama at Birmingham (UAB) says low potassium levels produce an increased risk of death or hospitalization in patients with heart failure and chronic kidney disease (CKD).

10 Feb 2010

Low potassium levels increase risk of death in patients with heart failure and CKD

9 Feb 2010

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

Amgen today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints.

9 Feb 2010

3SBio announces Nephoxil collaboration and license agreement with Panacor Bioscience

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced a collaboration and license agreement with Panacor Bioscience Ltd. to develop and commercialize its Nephoxil(R) pharmaceutical product for the treatment of hyperphosphatemia in China.

8 Feb 2010

Kidney care advocates urge passage of key legislation for Georgia’s kidney patients

On Tuesday, February 9, kidney patients from across the state of Georgia will join Dialysis Patient Citizens (DPC) – a national, non-profit, patient-led organization representing approximately 1,300 members in Georgia and 22,000 members nationwide – in holding a briefing at the State Capitol, followed by a series of meetings with lawmakers and staff, urging the passage of key legislation this year that would help thousands of Georgia’s kidney failure patients who are struggling to access health insurance for the medical care they need.

6 Feb 2010

Artificial pancreas can help manage diabetes in kids overnight

In a landmark study in children and teenagers with type 1 diabetes, JDRF-funded researchers at the University of Cambridge showed that using a first-generation artificial pancreas system overnight can lower the risk of low blood sugar emergencies while sleeping, and at the same time improve diabetes control.

6 Feb 2010

AMAG Pharmaceuticals releases safety update on Feraheme Injection

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today provided a safety update on Feraheme® (ferumoxytol) Injection for intravenous use.

6 Feb 2010

Patients with mild gallstone pancreatitis can be operated within 48 hours of admission

Patients with mild gallstone pancreatitis usually stay in the hospital for several days, waiting for the symptoms to subside, before undergoing surgery to remedy the condition. A new study from researchers at Los Angeles Biomedical Research Institute (LA BioMed) indicates patients may no longer have to wait so long for surgery and could leave the hospital sooner.

5 Feb 2010

Patients with high levels of proteinuria have increased risk of all-cause death

Patients with high levels of proteinuria (protein in urine) in addition to another marker of reduced kidney function had an associated increased risk of all-cause death, heart attack or progression to kidney failure, according to a study in the February 3 issue of JAMA.

3 Feb 2010

One-third of doctors and diabetes patients prioritize health conditions differently

About one-third of doctors and their patients with diabetes do not see eye to eye on the most important health conditions to manage, according to a survey by the University of Michigan Medical School.

3 Feb 2010

Kidney Disease News and Research

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

Childhood obesity: Strongest predictor of premature death

Scientists discover molecular pathway to regenerate damaged kidney tissues

Simple protein urine test may help detect early kidney disease in people with lupus

Study shows benefits of stent grafts over balloon angioplasty for patients who undergo dialysis

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Researchers investigate risk factors for childhood obesity

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Low potassium levels increase risk of death in patients with heart failure and CKD

Low potassium levels increase risk of death in patients with heart failure and CKD

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

3SBio announces Nephoxil collaboration and license agreement with Panacor Bioscience

Kidney care advocates urge passage of key legislation for Georgia’s kidney patients

Artificial pancreas can help manage diabetes in kids overnight

AMAG Pharmaceuticals releases safety update on Feraheme Injection

Patients with mild gallstone pancreatitis can be operated within 48 hours of admission

Patients with high levels of proteinuria have increased risk of all-cause death

One-third of doctors and diabetes patients prioritize health conditions differently

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News